KPI Therapeutics Inc., of Seattle, presented preclinical data at the Inflammatory Skin Diseases Summit at the New York Academy of Medicine, demonstrating that its KPI-150 peptide has potential therapeutic benefit in atopic dermatitis and other dermatologic inflammatory diseases when administered topically in animal models. Read More
Keryx Biopharmaceuticals Inc., of New York, reported case study data at the American Society of Nephrology's Kidney Week meeting in Chicago, which showed that Auryxia (ferric citrate) lowered and maintained serum phosphorus levels in chronic kidney disease (CKD) patients on dialysis. Read More
Aclaris Therapeutics Inc., of Malvern, Pa., priced its public offering of 4 million shares at $22.75 apiece, with gross proceeds expected to total about $91 million. Read More
NEW DELHI – Marking what may be a first, Mylan NV and Biocon Ltd. have submitted Mylan's biologics license application (BLA) to the FDA for a proposed biosimilar of branded trastuzumab, MYL-1401O, to treat certain forms of breast and gastric cancers. Read More
As partner Mylan NV makes ready to launch in Canada the erectile dysfunction (ED) drug-device combo Vitaros (alprostadil cream) – approved there as well as certain countries in Europe, Latin America and the Middle East – Apricus Biosciences Inc. heard from the FDA what's necessary in the U.S. to resolve issues in the complete response letter (CRL) dating back to 2008. Read More
HONG KONG – China's health care sector is seeing a surge of mergers and acquisitions thanks to regulatory reforms that are expected to drive development. Case in point is Sciclone Pharmaceuticals Inc., a San Francisco-based drug developer that markets drugs in China. The company confirmed this month that it received an unsolicited $570 million acquisition offer. Read More
Celgene Corp., a long-time backer of privately held Triphase Accelerator Corp., has acquired the company's ocean-sourced proteasome inhibitor, marizomib, currently in development for the I.V. treatment of glioblastoma and relapsed/refractory multiple myeloma, the home territory of Celgene's Revlimid (lenalidomide). Read More
In a terse bulleted statement, Globeimmune Inc. disclosed what sounded like its death knell: dissolution of its license agreement with Gilead Sciences Inc. for hepatitis B virus (HBV) candidate GS-4774, wholesale resignation of the company's CEO and board and termination of its office and manufacturing space. Read More
